XML 41 R21.htm IDEA: XBRL DOCUMENT v3.25.0.1
Product Revenue
 12 Months Ended
Dec. 31, 2024
Revenue from Contract with Customer [Abstract]  
Product Revenue Product Revenue
The Company’s product revenue is primarily derived from the sale of its internally developed products BRUKINSA and TEVIMBRA in the U.S., China, and other regions; XGEVA, BLINCYTO and KYPROLIS in China under a license from Amgen; REVLIMID® and VIDAZA® in China under a license from BMS; and POBEVCY® in China under a license from Bio-Thera.
The table below presents the Company’s net product sales for the years ended December 31, 2024, 2023 and 2022.
 Year Ended December 31,
 202420232022
 $$$
Product revenue - gross4,786,744 2,718,969 1,438,440 
Less: Rebates and sales returns(1,007,198)(529,117)(183,828)
Product revenue - net3,779,546 2,189,852 1,254,612 
The following table disaggregates net product revenue by product for the years ended December 31, 2024, 2023 and 2022.
Year Ended December 31,
202420232022
$$$
BRUKINSA®
2,644,226 1,290,396 564,651 
Tislelizumab620,836 536,620 422,885 
XGEVA®
224,403 92,828 63,398 
BLINCYTO®
74,331 54,342 36,107 
KYPROLIS®
66,171 39,799 13,696 
POBEVCY®
53,509 56,547 38,124 
REVLIMID®
36,028 76,018 79,049 
Other60,042 43,302 36,702 
Total product revenue - net3,779,546 2,189,852 1,254,612 
The following table presents the roll-forward of accrued sales chargebacks, rebates, returns and other deductions for the years ended December 31, 2024 and 2023.
 Rebates, Returns and Other DeductionsContra AR AccrualsTotal
 $$
Balance at December 31, 202241,817 8,580 50,397 
Amounts charged against product revenue275,031 254,086 529,117 
Payments and credits(176,912)(232,231)(409,143)
Balance at December 31, 2023139,936 30,435 170,371 
Amounts charged against product revenue491,756 515,442 1,007,198 
Payments and credits(396,092)(495,178)(891,270)
Balance at December 31, 2024235,600 50,699 286,299